Body mass index does not impact on molecular response rate of chronic myeloid leukaemia patients treated frontline with second generation tyrosine kinase inhibitors

Br J Haematol. 2018 Aug;182(3):427-429. doi: 10.1111/bjh.14783. Epub 2017 Jul 5.

Authors

Matteo Molica¹, Martina Canichella¹, Gioia Colafigli¹, Roberto Latagliata¹, Daniela Diverio¹, Giuliana Alimena¹, Robin Foà¹, Massimo Breccia¹

Affiliation

¹ Haematology, Department of Cellular Biotechnologies and Haematology, Policlinico Umberto 1, Sapienza University, Rome, Italy.

PMID: 28677850
DOI: 10.1111/bjh.14783

No abstract available

Keywords: body mass index; chronic myeloid leukaemia; dasatinib; nilotinib; prognosis.

Publication types

Letter

MeSH terms

Adult
Antineoplastic Agents / therapeutic use
Body Mass Index*
Dasatinib / therapeutic use
Female
Humans
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / diagnosis
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy*
Male
Middle Aged
Prognosis
Protein Kinase Inhibitors / therapeutic use
Protein-Tyrosine Kinases / antagonists & inhibitors
Pyrimidines / therapeutic use
Remission Induction / methods

Substances

Antineoplastic Agents
Protein Kinase Inhibitors
Pyrimidines
Protein-Tyrosine Kinases
nilotinib
Dasatinib